Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franco Maggiolo

Showing results (111-120 of 150) with videos related to

Pageof 15
Sort By:
The Journal of Antimicrobial Chemotherapy|July 22, 2009
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weightingMaurizio Zazzi, Mattia Prosperi, Ilaria Vicenti, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|September 26, 2020
Marked decrease in acquired resistance to antiretrovirals in latest years in ItalyAlessia Lai, Marco Franzetti, Annalisa Bergna, et al.
Journal of Clinical Medicine|January 21, 2022
Correlates of Treatment and Disease Burden in People Living with HIV (PLHIV) in ItalyAntonella Cingolani, Alessandro Tavelli, Franco Maggiolo, et al.
International Journal of Antimicrobial Agents|July 12, 2022
Impact of pre-existent drug resistance on virological efficacy of single-tablet regimens in people living with HIVGiulia Stella, Lorenzo Volpicelli, Domenico Di Carlo, et al.
AIDS (London, England)|February 13, 2024
Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapyChloe Orkin, Andrea Antinori, Jürgen K Rockstroh, et al.
BMC Public Health|April 18, 2015
Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: a multicentre cohort studyElena Raffetti, Laura Albini, Daria Gotti, et al.
Eclinicalmedicine|May 18, 2023
Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trialsPaul E Sax, José R Arribas, Chloe Orkin, et al.
Journal of Hepatology|August 4, 2004
A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patientsMassimo Puoti, Barbara Zanini, Gian Paolo Quinzan, et al.
Plos One|April 25, 2014
Survival in HIV-infected patients after a cancer diagnosis in the cART Era: results of an italian multicenter studyDaria Gotti, Elena Raffetti, Laura Albini, et al.
Infectious Diseases and Therapy|March 9, 2021
Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label TrialFranco Maggiolo, Giuliano Rizzardini, Jean-Michel Molina, et al.
Pageof 15

Showing results (111-120 of 150) with videos related to

Sort By:
Pageof 15
The Journal of Antimicrobial Chemotherapy|July 22, 2009
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weightingMaurizio Zazzi, Mattia Prosperi, Ilaria Vicenti, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|September 26, 2020
Marked decrease in acquired resistance to antiretrovirals in latest years in ItalyAlessia Lai, Marco Franzetti, Annalisa Bergna, et al.
Journal of Clinical Medicine|January 21, 2022
Correlates of Treatment and Disease Burden in People Living with HIV (PLHIV) in ItalyAntonella Cingolani, Alessandro Tavelli, Franco Maggiolo, et al.
International Journal of Antimicrobial Agents|July 12, 2022
Impact of pre-existent drug resistance on virological efficacy of single-tablet regimens in people living with HIVGiulia Stella, Lorenzo Volpicelli, Domenico Di Carlo, et al.
AIDS (London, England)|February 13, 2024
Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapyChloe Orkin, Andrea Antinori, Jürgen K Rockstroh, et al.
BMC Public Health|April 18, 2015
Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: a multicentre cohort studyElena Raffetti, Laura Albini, Daria Gotti, et al.
Eclinicalmedicine|May 18, 2023
Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trialsPaul E Sax, José R Arribas, Chloe Orkin, et al.
Journal of Hepatology|August 4, 2004
A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patientsMassimo Puoti, Barbara Zanini, Gian Paolo Quinzan, et al.
Plos One|April 25, 2014
Survival in HIV-infected patients after a cancer diagnosis in the cART Era: results of an italian multicenter studyDaria Gotti, Elena Raffetti, Laura Albini, et al.
Infectious Diseases and Therapy|March 9, 2021
Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label TrialFranco Maggiolo, Giuliano Rizzardini, Jean-Michel Molina, et al.
Pageof 15